Fiorella Meneghetti

Prof. Dr. Fiorella Meneghetti

Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via L. Mangiagalli 25, 20133 Milano, Italy
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
GTG. Tibolla
G. Tibolla
Giuseppe NorataGiuseppe Norata
Giuseppe Norata
RAR. Artali
R. Artali
FMFiorella Meneghetti
Fiorella Meneghetti
Alberico Luigi Catapano‌Alberico Luigi Catapano‌
Alberico Luigi Catapano‌

1 January 2010 in Atherosclerosis
Verified
Journal Article
Closed access
Giuseppe NorataGiuseppe Norata
Giuseppe Norata
KGKatia Garlaschelli
Katia Garlaschelli
LGLiliana Grigore
Liliana Grigore
SRSara Raselli
Sara Raselli
STSimona Tramontana
Simona Tramontana
Alberico Luigi Catapano‌Alberico Luigi Catapano‌
Alberico Luigi Catapano‌

28 April 2011 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
DMDaniela Masciocchi
Daniela Masciocchi
Arianna GelainArianna Gelain
Arianna Gelain
Stefania VillaStefania Villa
Stefania Villa
FMFiorella Meneghetti
Fiorella Meneghetti
DBDaniela Barlocco
Daniela Barlocco
Signal transducer and activator of transcription 3 (STAT3) is an oncogenic protein whose inhibition is sought for the prevention and treatment of cancer. In this review, the validated therapeutic strategy to block aberrant activity of STAT3 in many tumor cell lines is evaluated by presenting the most promising inhibitors to date. The compounds are discussed in classes based on their different mechanisms of action, which are critically explained. In addition, their future clinical development as anticancer agents is considered. Furthermore, the efforts devoted to the comprehension of the structure-activity relationships and to the identification of the biological effects are brought to attention. The synthetic and technological approaches recently developed to overcome the difficulties in the obtainment of clinically suitable drugs are also presented.

1 July 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
Laurent Roberto ChiarelliLaurent Roberto Chiarelli
Laurent Roberto Chiarelli
MMMatteo Mori
Matteo Mori
DBDaniela Barlocco
Daniela Barlocco
GBGiangiacomo Beretta
Giangiacomo Beretta
AGArianna Gelain
Arianna Gelain
FMFiorella Meneghetti
Fiorella Meneghetti
We report on the virtual screening, synthesis, and biological evaluation of new furan derivatives targeting Mycobacterium tuberculosis salicylate synthase (MbtI). A receptor-based virtual screening procedure was applied to screen the Enamine database, identifying two compounds, I and III, endowed with a good enzyme inhibitory activity. Considering the most active compound I as starting point for the development of novel MbtI inhibitors, we obtained new derivatives based on the furan scaffold. Among the SAR performed on this class, compound 1a emerged as the most potent MbtI inhibitor reported to date (Ki = 5.3 μM). Moreover, compound 1a showed a promising antimycobacterial activity (MIC99 = 156 μM), which is conceivably related to mycobactin biosynthesis inhibition.

12 February 2016 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
MSMattia Stucchi
Mattia Stucchi
GLGiordano Lesma
Giordano Lesma
FMFiorella Meneghetti
Fiorella Meneghetti
GRGiulia Rainoldi
Giulia Rainoldi
Alessandro SacchettiAlessandro Sacchetti
Alessandro Sacchetti
ASAlessandra Silvani
Alessandra Silvani

3 September 2015 in Organic Letters
Verified
Journal Article
Closed access
ABAndrea Bonetti
Andrea Bonetti
sara pellegrinosara pellegrino
sara pellegrino
PDPriyadip Das
Priyadip Das
SYSivan Yuran
Sivan Yuran
RBRaffaella Bucci
Raffaella Bucci
Maria Luisa GelmiMaria Luisa Gelmi
Maria Luisa Gelmi